The findings are the first to demonstrate that the vaccine remains effective for many months, an outcome that doctors and scientists had desperately hoped for because it suggests that people being vaccinated now should be protected at least until the autumn when boosters may be ready.Īnalysis of participants in the phase 3 trial, which has enrolled 46,307 people, identified 927 symptomatic Covid cases. The level of protection is only marginally lower than the 95% achieved soon after vaccination. In a statement released on Thursday, the companies reported efficacy of 91.3% against any symptoms of the disease in participants assessed up to six months after their second shot.
The coronavirus vaccine developed by Pfizer and its German partner BioNTech protects against symptomatic Covid for up to six months, an updated analysis of clinical trial data has found.
0 kommentar(er)
